Clinical TrialsThe ongoing, fully-funded phase 3 breast cancer trial for RLY-2608 shows promising results, with its phase 1b progression-free survival doubling the expected control performance.
Commercial ProspectsThe commercial prospects for RLY-2608 are compelling, with several worse drugs in the same setting having quickly sold over $500 million.
Competitive AdvantageRLAY leads all competitors of its mutant-selective class by 18-24 months, suggesting a significant competitive advantage.